How to Evaluate Compounded Tirzepatide Vendors: A 2026 Framework

What "Compounded Tirzepatide" Actually Means in 2026

Tirzepatide is the active ingredient in two FDA-approved brand-name products from Eli Lilly: Mounjaro, approved for type 2 diabetes in 2022, and Zepbound, approved for obesity in 2023. It is a dual agonist that activates both the GLP-1 and GIP receptors, with an approved dose range of 2.5 mg to 15 mg. Compounded tirzepatide is a pharmacy-made version of that same molecule, prepared outside Lilly's manufacturing process.

Compounding is legal under specific conditions, but the conditions tightened after the shortage ended. The distinction that drives every vendor evaluation is which legal framework a pharmacy operates under: 503A or 503B. Get that right and most of the other questions answer themselves.

The Shortage List and Why It Matters

Compounding pharmacies were broadly permitted to compound tirzepatide while it sat on the FDA drug shortage list. That listing gave 503A pharmacies a legal basis to make the drug at scale because the approved product was hard to get. The FDA removed tirzepatide from the drug shortage list in October 2024, and the enforcement deadlines that compounders had to meet followed in early 2025. Once a drug comes off that list, the broad shortage-based permission to compound it goes away, and the legal lane narrows considerably. This is the regulatory backdrop a reader needs before evaluating any source.

What the "Active Ingredient" Claim Means

Not all compounded tirzepatide is chemically identical to the approved brand product. Mounjaro and Zepbound use tirzepatide in its base free-acid form. Some compounders use a salt form, such as tirzepatide acetate, which can be cheaper to source. The FDA has not approved any salt-form substitution as equivalent to the base form. A vendor's Certificate of Analysis should specify which form is in the vial, and a careful buyer asks the question directly rather than assuming.

The Two Legal Frameworks: 503A vs 503B

Almost everything about a vendor's legitimacy traces back to its license type. Both are defined under the federal Food, Drug, and Cosmetic Act, and they describe two genuinely different kinds of pharmacy with different oversight and different quality baselines.

503A: State-Licensed, Patient-Specific Pharmacies

• Licensed and overseen primarily by a state pharmacy board, not the FDA directly.
• Must have a valid patient-specific prescription on file before compounding.
• Typically smaller-scale operations not subject to routine federal inspection.
• Quality control varies by pharmacy. PCAB accreditation is a positive signal but not a guarantee.

503B: FDA-Registered Outsourcing Facilities

• Registered directly with the FDA as an outsourcing facility.
• Subject to FDA Current Good Manufacturing Practice (CGMP) inspections.
• Can compound without a patient-specific prescription for office or clinic use.
• Higher baseline quality-control infrastructure. You can verify registration on the FDA's published outsourcing facility list.

What Neither License Covers

The Prescription Requirement: A Non-Negotiable Red Line

Every legitimate compounding pharmacy, whether 503A or 503B, dispenses against a valid prescription from a licensed US healthcare provider. No prescription means not legitimate. This is the single fastest quality filter you have, and it costs nothing to apply: look at the intake flow and see whether a real clinical evaluation happens before the vial ships.

What a Legitimate Telehealth Prescription Pathway Looks Like

• A licensed prescriber (MD, DO, NP, or PA) evaluates the patient.
• The prescription is sent directly to the pharmacy. The patient does not hand-carry or relay it.
• A written prescription or e-prescription is on file before anything is dispensed.
• The prescriber is licensed in the patient's own state.

Red Flags Around the Prescription Step

• "No prescription needed" or "prescription included" with no actual clinical evaluation.
• A vendor that also runs a separate "research use only" product line selling the same compound without any prescription.
• An offshore checkout that skips US prescriber involvement entirely.

How to Evaluate Compounded Tirzepatide Vendors With Third-Party Testing

Licensing and prescriptions tell you whether a source is legal. Third-party testing tells you whether the product is what it claims to be. Two independent services have become the 2026 standard reference points for peptide-compound testing: Finnrick Analytics and Janoshik Analytical. Neither is a vendor; both are testing and verification services, which is why naming them is factual rather than an endorsement of any pharmacy.

What Third-Party Testing Verifies

• Identity: Is the compound actually tirzepatide, and in which form?
• Purity: What share of the sample is the target compound versus impurities?
• Concentration: Does the stated dose match the actual amount in the vial?
• Sterility: Batch-specific results from a sterile-fill operation.

Finnrick Analytics

Finnrick Analytics has analyzed roughly 6,937 samples across 205 vendors and publishes per-vendor pages with historical test results. That history is the value: it lets you see a vendor's pass-and-fail pattern over time rather than a single snapshot. Multiple consistent results from the same source are a far stronger signal than one isolated test a vendor chose to share.

Janoshik Analytical

Janoshik Analytical operates a public Certificate of Analysis verification portal at janoshik.com/verification. You can look up a batch COA number there to confirm it is genuine rather than fabricated. When a source links out to Janoshik for batch-level COAs, it is letting you verify the result directly. A Janoshik-verified COA proves the specific batch was tested, not merely that the vendor claims to test.

How to Request and Read a COA

A usable COA lists the compound name, the batch number, the purity result, the test method (HPLC is the standard), the lab name, and the test date. The most important cross-check is simple: match the batch number on the COA to the batch number printed on your vial label. A COA for a different lot tells you nothing about the vial in your hand.

US-Warehousing and the CBP Seizure Risk

Where a product is formulated and shipped from is a quality signal in itself. Customs and Border Protection seized more than 5,000 China-direct peptide shipments between December 2025 and March 2026. That enforcement wave hit gray-market research-chemical sellers, not licensed compounding pharmacies, but it tells you exactly where the risk sits.

What Happened in the 2025 to 2026 Enforcement Window

• The seizures targeted direct-from-China shipments that bypassed any licensed US pharmacy.
• Some gray-market operations ship tirzepatide without a prescription using China-sourced active ingredient.
• Licensed US compounding pharmacies use domestically sourced active ingredient and ship within the US, so they are not exposed to import-seizure risk.

What US-Warehousing Means for Evaluation

• Product formulated and stored in a licensed US pharmacy carries no import-seizure risk.
• Direct-from-China "tirzepatide" orders combine seizure risk, unknown quality, and no prescription compliance. Do not use them.
• Quick test: if a vendor ships from outside the US or routes through a non-US pharmacy, it is not a licensed US compounding pharmacy.

Watch: Can You Trust a Compounding Pharmacy?

Dr. Mike Hansen, a board-certified internal medicine physician, walks through the questions to ask when a compounding pharmacy dispenses a GLP-1 drug. Note that the video was published in 2023, so its regulatory timeline predates the October 2024 shortage-list change covered above. The evaluation logic, however, holds up well.

The Compounded Tirzepatide Vendors Evaluation Framework: Five Signals

Here is the whole method on one screen. Each signal maps back to a section above. If a source clears all five, it is operating the way a legitimate licensed pharmacy should. If it fails any one of them, stop.

For the broader reasoning behind these criteria across compounds, see GLP3Planner's vendor safety methodology. This logic does not extend to retatrutide: it remains investigational, and the FDA states it cannot be used in compounding under federal law, so no compounding pharmacy can lawfully supply it (see why compounded retatrutide is prohibited).

Using the Tirzepatide Calculator After Sourcing

Once you have evaluated a source and obtained a vial, the next problem is practical: compounded tirzepatide usually arrives as a lyophilized powder you reconstitute yourself, and the concentration depends on how much bacteriostatic water you add. Standard tirzepatide dosing starts at 2.5 mg and titrates every 4 weeks toward a maximum of 15 mg. Compounded vials commonly come in 5 mg, 10 mg, 15 mg, or 30 mg sizes, so the math changes with each vial.

The free tirzepatide calculator handles the conversion: enter your vial size and water volume and it returns the units per dose, then maps your titration schedule. If you also need help reconstituting, the guide to reconstituting compounded tirzepatide walks through the steps.